Target Gene/Pathway Pathway / Gene


Search results


No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank 指定難病告示番号
1 SIGMAR1 2件: Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
2 SIGMAR1 2件: Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
3 SIGMAR1 2件: Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
4 TUBB3 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
5 TUBB3 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
6 TUBB3 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
7 TUBB4A 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
8 TUBB4A 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
9 TUBB4A 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
10 TUBB4B 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
11 TUBB4B 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
12 TUBB4B 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
13 CD52 - D02802 Alemtuzumab 15件: 46, 49, 51, 60, 62, 63, 65, 85, 96, 164, 234, 283, 284, 285, 326
14 TNFSF13B 4件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D03068 Belimumab 12件: 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300
15 TNFSF13B 4件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D09704 Atacicept 4件: 13, 46, 49, 66
16 TNFSF13B 4件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D10083 Tabalumab 2件: 46, 49
17 CYSLTR1 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction D00529 Montelukast 8件: 6, 13, 46, 61, 63, 85, 98, 228
18 CYSLTR1 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction D08229 Montelukast 8件: 6, 13, 46, 61, 63, 85, 98, 228
19 IL17F 4件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Inflammatory bowel disease D11550 Bimekizumab 3件: 46, 97, 271
20 TNFRSF13C 5件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Human T-cell leukemia virus 1 infection, Primary immunodeficiency D12151 Ianalumab 5件: 35, 46, 49, 53, 95
21 CCR5 9件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, Endocytosis, Toxoplasmosis, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis D06670 Maraviroc 2件: 46, 84
22 CNR1 4件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D00306 Dronabinol 8件: 2, 8, 13, 36, 46, 96, 271, 298
23 CNR1 4件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D10915 Cannabidiol 19件: 2, 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
24 CNR2 1件: Neuroactive ligand-receptor interaction D00306 Dronabinol 4件: 46, 96, 271, 298
25 CNR2 1件: Neuroactive ligand-receptor interaction D10915 Cannabidiol 14件: 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
26 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
27 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
28 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D02769 Adenosine phosphate 1件: 46
29 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
30 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
31 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D02769 Adenosine phosphate 1件: 46
32 ADORA2B 5件: Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D02769 Adenosine phosphate 1件: 46
33 ADORA3 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02769 Adenosine phosphate 1件: 46
34 ADORA3 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10971 Piclidenoson 1件: 46
35 CSF2 16件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Shigellosis, Amoebiasis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Coronavirus disease - COVID-19, Transcriptional misregulation in cancer, Acute myeloid leukemia, Rheumatoid arthritis D11343 Otilimab 2件: 46, 256
36 CSF2RA 4件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D09930 Mavrilimumab 2件: 41, 46
37 CSF3R 5件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03235 Filgrastim 34件: 2, 6, 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331
38 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine 3件: 46, 70, 96
39 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine 3件: 46, 70, 96
40 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine 3件: 46, 70, 96
41 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine 3件: 46, 70, 96
42 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine 3件: 46, 70, 96
43 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine 3件: 46, 70, 96
44 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine 3件: 46, 70, 96
45 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine 3件: 46, 70, 96
46 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine 3件: 46, 70, 96
47 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine 3件: 46, 70, 96
48 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
49 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine 3件: 46, 70, 96
50 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
51 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine 3件: 46, 70, 96
52 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine 3件: 46, 70, 96
53 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
54 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine 3件: 46, 70, 96
55 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
56 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine 3件: 46, 70, 96
57 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine 3件: 46, 70, 96
58 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
59 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine 3件: 46, 70, 96
60 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine 13件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
61 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine 3件: 46, 70, 96
62 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00095 Epinephrine 3件: 46, 70, 96
63 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00996 Epinephrine 3件: 46, 70, 96
64 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02149 Epinephrine 3件: 46, 70, 96
65 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine 3件: 46, 70, 96
66 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00996 Epinephrine 3件: 46, 70, 96
67 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02149 Epinephrine 3件: 46, 70, 96
68 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine 3件: 46, 70, 96
69 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00996 Epinephrine 3件: 46, 70, 96
70 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02149 Epinephrine 3件: 46, 70, 96
71 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00251 Captopril 8件: 6, 17, 46, 86, 96, 97, 107, 271
72 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00362 Lisinopril 7件: 19, 46, 49, 66, 67, 113, 222
73 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00421 Ramipril 7件: 46, 49, 66, 67, 113, 218, 257
74 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00621 Enalapril 6件: 19, 46, 66, 113, 210, 222
75 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D07892 Enalapril 6件: 19, 46, 66, 113, 210, 222
76 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D08131 Lisinopril 7件: 19, 46, 49, 66, 67, 113, 222
77 DHFR 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D00142 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
78 DHFR 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D02115 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
79 DHODH 3件: Pyrimidine metabolism, Metabolic pathways, Biosynthesis of cofactors D00749 Leflunomide 12件: 11, 40, 46, 49, 53, 66, 107, 162, 224, 270, 271, 300
80 NQO1 7件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D00564 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
81 NQO1 7件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D01280 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
82 NQO1 7件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D08682 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
83 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D01226 Sulpiride 5件: 2, 6, 17, 46, 70
84 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08549 Sulpiride 5件: 2, 6, 17, 46, 70
85 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00150 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
86 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00357 Losartan 18件: 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
87 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D02014 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
88 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D08146 Losartan 18件: 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
89 AGTR2 3件: Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system D00150 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
90 AGTR2 3件: Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system D02014 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
91 DHFR2 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D00142 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
92 DHFR2 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D02115 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
93 TUBB 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
94 TUBB 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
95 TUBB 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
96 EPOR 5件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03231 Erythropoietin 10件: 2, 6, 13, 18, 22, 46, 47, 70, 95, 96
97 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00105 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
98 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00554 Ethinylestradiol 4件: 13, 46, 49, 299
99 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00575 Mestranol 2件: 46, 49
100 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01413 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
101 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01617 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
102 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01953 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
103 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D02217 Raloxifene 1件: 46
104 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04061 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
105 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04063 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
106 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04064 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
107 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04065 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
108 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D08465 Raloxifene 1件: 46
109 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00105 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
110 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00575 Mestranol 2件: 46, 49
111 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01413 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
112 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01617 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
113 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01953 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
114 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D02217 Raloxifene 1件: 46
115 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04061 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
116 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04063 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
117 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04064 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
118 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04065 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
119 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D08465 Raloxifene 1件: 46
120 F10 1件: Complement and coagulation cascades D07086 Rivaroxaban 5件: 46, 49, 75, 91, 210
121 F10 1件: Complement and coagulation cascades D09710 Edoxaban 2件: 46, 88
122 FCER1A 4件: Sphingolipid signaling pathway, Phospholipase D signaling pathway, Fc epsilon RI signaling pathway, Asthma D05251 Omalizumab 7件: 46, 53, 65, 98, 162, 226, 299
123 FCGRT - D11666 Nipocalimab 4件: 46, 49, 53, 61
124 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D00939 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299
125 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D00942 Risedronic acid 9件: 46, 50, 66, 93, 95, 96, 107, 113, 274
126 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D01968 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
127 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D03234 Risedronic acid 9件: 46, 50, 66, 93, 95, 96, 107, 113, 274
128 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D06378 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
129 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D06379 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
130 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D07119 Alendronic acid 7件: 19, 41, 46, 50, 271, 274, 299
131 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D08056 Ibandronate 3件: 46, 49, 274
132 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D08484 Risedronic acid 9件: 46, 50, 66, 93, 95, 96, 107, 113, 274
133 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D08689 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
134 POLA2 1件: DNA replication D03546 Clofarabine 6件: 46, 49, 60, 96, 234, 326
135 MTOR 51件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy D00753 Sirolimus 41件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331
136 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
137 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
138 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
139 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
140 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
141 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
142 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
143 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
144 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
145 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
146 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
147 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
148 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
149 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
150 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
151 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
152 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
153 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
154 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
155 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
156 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
157 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
158 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
159 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
160 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
161 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
162 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
163 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
164 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
165 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
166 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
167 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
168 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
169 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
170 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
171 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
172 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
173 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
174 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
175 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
176 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
177 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
178 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
179 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
180 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
181 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
182 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
183 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
184 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
185 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
186 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
187 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
188 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
189 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
190 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
191 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
192 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
193 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
194 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
195 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
196 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
197 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
198 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
199 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
200 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
201 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
202 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
203 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
204 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
205 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
206 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
207 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
208 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
209 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
210 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
211 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
212 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
213 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
214 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
215 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
216 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
217 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
218 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
219 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
220 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
221 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
222 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
223 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
224 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
225 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
226 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
227 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
228 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
229 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
230 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
231 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
232 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
233 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
234 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
235 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
236 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
237 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
238 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
239 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
240 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
241 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
242 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
243 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
244 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
245 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
246 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
247 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
248 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
249 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
250 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
251 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
252 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
253 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
254 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
255 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
256 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
257 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
258 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
259 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
260 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
261 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
262 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
263 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
264 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
265 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
266 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
267 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
268 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
269 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
270 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
271 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
272 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
273 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
274 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
275 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
276 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
277 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
278 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
279 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
280 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
281 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
282 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
283 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
284 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
285 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
286 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
287 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
288 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
289 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
290 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
291 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
292 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
293 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
294 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
295 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
296 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
297 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
298 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
299 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
300 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
301 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
302 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
303 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
304 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
305 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
306 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
307 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
308 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
309 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
310 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
311 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
312 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
313 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
314 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
315 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
316 ABL1 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D01441 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
317 ABL1 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
318 GHR 5件: Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action D02691 Somatotropin 23件: 2, 3, 13, 19, 46, 65, 74, 75, 76, 78, 96, 107, 113, 187, 191, 193, 195, 236, 238, 265, 274, 276, 299
319 GNRHR 2件: Neuroactive ligand-receptor interaction, GnRH signaling pathway D01685 Cetrorelix 1件: 46
320 GNRHR 2件: Neuroactive ligand-receptor interaction, GnRH signaling pathway D07665 Cetrorelix 1件: 46
321 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
322 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
323 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
324 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
325 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
326 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
327 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
328 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
329 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
330 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
331 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
332 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
333 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
334 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
335 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
336 NR3C1 1件: Neuroactive ligand-receptor interaction D00088 Hydrocortisone 9件: 46, 53, 75, 78, 81, 83, 97, 98, 299
337 NR3C1 1件: Neuroactive ligand-receptor interaction D00244 Betamethasone 5件: 46, 83, 90, 96, 235
338 NR3C1 1件: Neuroactive ligand-receptor interaction D00292 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
339 NR3C1 1件: Neuroactive ligand-receptor interaction D00385 Triamcinolone 9件: 46, 56, 70, 90, 96, 107, 162, 226, 298
340 NR3C1 1件: Neuroactive ligand-receptor interaction D00407 Methylprednisolone 31件: 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
341 NR3C1 1件: Neuroactive ligand-receptor interaction D00472 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
342 NR3C1 1件: Neuroactive ligand-receptor interaction D00473 Prednisone 34件: 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331
343 NR3C1 1件: Neuroactive ligand-receptor interaction D00751 Methylprednisolone 31件: 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
344 NR3C1 1件: Neuroactive ligand-receptor interaction D00972 Betamethasone 5件: 46, 83, 90, 96, 235
345 NR3C1 1件: Neuroactive ligand-receptor interaction D00975 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
346 NR3C1 1件: Neuroactive ligand-receptor interaction D00979 Methylprednisolone 31件: 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
347 NR3C1 1件: Neuroactive ligand-receptor interaction D00980 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
348 NR3C1 1件: Neuroactive ligand-receptor interaction D00981 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
349 NR3C1 1件: Neuroactive ligand-receptor interaction D00982 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
350 NR3C1 1件: Neuroactive ligand-receptor interaction D00983 Triamcinolone 9件: 46, 56, 70, 90, 96, 107, 162, 226, 298
351 NR3C1 1件: Neuroactive ligand-receptor interaction D00984 Triamcinolone 9件: 46, 56, 70, 90, 96, 107, 162, 226, 298
352 NR3C1 1件: Neuroactive ligand-receptor interaction D00985 Triamcinolone 9件: 46, 56, 70, 90, 96, 107, 162, 226, 298
353 NR3C1 1件: Neuroactive ligand-receptor interaction D01239 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
354 NR3C1 1件: Neuroactive ligand-receptor interaction D01272 Clobetasol propionate 2件: 46, 162
355 NR3C1 1件: Neuroactive ligand-receptor interaction D01357 Betamethasone 5件: 46, 83, 90, 96, 235
356 NR3C1 1件: Neuroactive ligand-receptor interaction D01402 Betamethasone 5件: 46, 83, 90, 96, 235
357 NR3C1 1件: Neuroactive ligand-receptor interaction D01510 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
358 NR3C1 1件: Neuroactive ligand-receptor interaction D01615 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
359 NR3C1 1件: Neuroactive ligand-receptor interaction D01632 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
360 NR3C1 1件: Neuroactive ligand-receptor interaction D01637 Betamethasone 5件: 46, 83, 90, 96, 235
361 NR3C1 1件: Neuroactive ligand-receptor interaction D01948 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
362 NR3C1 1件: Neuroactive ligand-receptor interaction D01998 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
363 NR3C1 1件: Neuroactive ligand-receptor interaction D02032 Betamethasone 5件: 46, 83, 90, 96, 235
364 NR3C1 1件: Neuroactive ligand-receptor interaction D02156 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
365 NR3C1 1件: Neuroactive ligand-receptor interaction D02174 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
366 NR3C1 1件: Neuroactive ligand-receptor interaction D02286 Betamethasone 5件: 46, 83, 90, 96, 235
367 NR3C1 1件: Neuroactive ligand-receptor interaction D02591 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
368 NR3C1 1件: Neuroactive ligand-receptor interaction D02592 Dexamethasone 20件: 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
369 NR3C1 1件: Neuroactive ligand-receptor interaction D03301 Prednisolone 29件: 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
370 NR3C1 1件: Neuroactive ligand-receptor interaction D05000 Methylprednisolone 31件: 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
371 NR3C1 1件: Neuroactive ligand-receptor interaction D05001 Methylprednisolone 31件: 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
372 NR3C1 1件: Neuroactive ligand-receptor interaction D05002 Methylprednisolone 31件: 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
373 NR3C1 1件: Neuroactive ligand-receptor interaction D06216 Triamcinolone 9件: 46, 56, 70, 90, 96, 107, 162, 226, 298
374 NR3C1 1件: Neuroactive ligand-receptor interaction D07715 Clobetasol propionate 2件: 46, 162
375 NR3C1 1件: Neuroactive ligand-receptor interaction D07715 Clobetasol 3件: 46, 51, 162
376 NR3C1 1件: Neuroactive ligand-receptor interaction D08416 Prednisone acetate 4件: 46, 49, 162, 224
377 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00359 Lovastatin 11件: 6, 34, 46, 79, 156, 160, 195, 206, 263, 280, 310
378 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00434 Simvastatin 21件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310
379 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00887 Atorvastatin 18件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299
380 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00893 Pravastatin 9件: 13, 46, 49, 67, 79, 96, 164, 265, 333
381 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D01915 Rosuvastatin 11件: 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299
382 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D07474 Atorvastatin 18件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299
383 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D08410 Pravastatin 9件: 13, 46, 49, 67, 79, 96, 164, 265, 333
384 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D08492 Rosuvastatin 11件: 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299
385 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00364 Loratadine 4件: 13, 46, 89, 98
386 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00671 Fexofenadine 2件: 13, 46
387 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07407 Rupatadine 1件: 46
388 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07958 Fexofenadine 2件: 13, 46
389 HRH2 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D00318 Famotidine 7件: 6, 46, 61, 86, 98, 107, 300
390 IFNAR1 18件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D11082 Anifrolumab 2件: 46, 49
391 IFNAR2 17件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D11082 Anifrolumab 2件: 46, 49
392 IFNG 32件: Proteasome, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Fluid shear stress and atherosclerosis D04242 Fontolizumab 1件: 46
393 TUBB8 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
394 TUBB8 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
395 TUBB8 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
396 TUBB2B 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
397 TUBB2B 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
398 TUBB2B 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
399 IL1A 21件: MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
400 IL1B 44件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
401 IL1B 44件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09315 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269
402 IL1R1 13件: MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Amoebiasis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis D02934 Anakinra 19件: 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
403 IL4 16件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Leishmaniasis, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection D03117 Binetrakin 1件: 46
404 IL6 51件: EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
405 IL6 51件: EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D10080 Sirukumab 2件: 41, 46
406 IL6R 12件: EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer D02596 Tocilizumab 21件: 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331
407 IL6R 12件: EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer D10161 Sarilumab 5件: 41, 46, 84, 107, 271
408 IL10 22件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, FoxO signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Staphylococcus aureus infection, Tuberculosis, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Allograft rejection D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
409 IL12A 25件: Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis D09214 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
410 IL12B 25件: Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis D09214 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
411 IL17A 6件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis D09967 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271
412 IL17A 6件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis D11550 Bimekizumab 3件: 46, 97, 271
413 IMPDH1 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D01392 Mizoribine 8件: 46, 49, 51, 53, 66, 94, 222, 224
414 IMPDH2 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D01392 Mizoribine 8件: 46, 49, 51, 53, 66, 94, 222, 224
415 ITGA4 14件: PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D06886 Natalizumab 6件: 13, 15, 25, 46, 63, 96
416 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D03338 Calusterone 3件: 2, 46, 71
417 ITGAL 12件: Rap1 signaling pathway, Cell adhesion molecules, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Malaria, Staphylococcus aureus infection, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Rheumatoid arthritis, Viral myocarditis D03959 Efalizumab 9件: 11, 13, 37, 46, 49, 53, 61, 95, 96
418 JAK1 27件: EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
419 JAK1 27件: EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10308 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325
420 JAK1 27件: EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10653 Peficitinib 1件: 46
421 JAK1 27件: EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10871 Filgotinib 6件: 46, 53, 96, 97, 222, 271
422 JAK1 27件: EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10944 Itacitinib 5件: 46, 51, 60, 97, 228
423 JAK1 27件: EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10994 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271
424 JAK2 24件: EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
425 JAK2 24件: EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D10308 Baricitinib 13件: 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325
426 JAK2 24件: EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D10653 Peficitinib 1件: 46
427 JAK3 15件: Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Hepatitis B, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
428 JAK3 15件: Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Hepatitis B, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D10653 Peficitinib 1件: 46
429 KIT 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D01441 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
430 KIT 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
431 KIT 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D10229 Masitinib 6件: 2, 5, 6, 13, 46, 96
432 LTA 7件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, TNF signaling pathway, Type I diabetes mellitus, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection D00742 Etanercept 17件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298
433 LTA 7件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, TNF signaling pathway, Type I diabetes mellitus, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection D10187 Pateclizumab 1件: 46
434 LTB 3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis D08866 Baminercept 4件: 13, 46, 53, 97
435 MC2R 5件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome D00146 Corticotropin 15件: 2, 13, 14, 46, 49, 50, 66, 75, 78, 81, 84, 145, 193, 205, 222
436 MMP13 3件: IL-17 signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action D08859 Apratastat 1件: 46
437 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D00670 Donepezil 9件: 5, 6, 13, 46, 78, 124, 127, 156, 206
438 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D02068 Tacrine 3件: 46, 271, 299
439 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D07869 Donepezil 9件: 5, 6, 13, 46, 78, 124, 127, 156, 206
440 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D08555 Tacrine 3件: 46, 271, 299
441 MTNR1A 2件: Neuroactive ligand-receptor interaction, Circadian entrainment D02689 Ramelteon 3件: 6, 8, 46
442 MTNR1A 2件: Neuroactive ligand-receptor interaction, Circadian entrainment D08170 Melatonin 12件: 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202
443 MTNR1B 2件: Neuroactive ligand-receptor interaction, Circadian entrainment D02689 Ramelteon 3件: 6, 8, 46
444 MTNR1B 2件: Neuroactive ligand-receptor interaction, Circadian entrainment D08170 Melatonin 12件: 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202
445 SERPINC1 1件: Complement and coagulation cascades D03674 Enoxaparin 1件: 46
446 SERPINC1 1件: Complement and coagulation cascades D07510 Enoxaparin 1件: 46
447 ATP1A1 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
448 ATP1A2 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
449 ATP1A3 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
450 NFKB1 76件: Antifolate resistance, MAPK signaling pathway, Ras signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Apoptosis, Longevity regulating pathway, Cellular senescence, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Adipocytokine signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Pancreatic cancer, Prostate cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01146 Iguratimod 4件: 46, 51, 53, 271
451 ATP1A4 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
452 NPR1 10件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Vascular smooth muscle contraction, Thermogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Aldosterone synthesis and secretion D04051 Erythrityl tetranitrate 1件: 46
453 NPR1 10件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Vascular smooth muscle contraction, Thermogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Aldosterone synthesis and secretion D05147 Nesiritide 2件: 46, 58
454 NPR2 5件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Oxytocin signaling pathway D04051 Erythrityl tetranitrate 1件: 46
455 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
456 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01207 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
457 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01984 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
458 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D04056 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
459 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05259 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
460 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05261 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
461 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D07917 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
462 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D09339 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
463 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
464 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01207 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
465 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01984 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
466 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D04056 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
467 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05259 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
468 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05261 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
469 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D07917 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
470 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D09339 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
471 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02095 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
472 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D03783 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
473 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05113 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
474 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05312 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
475 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05462 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
476 OPRK1 1件: Neuroactive ligand-receptor interaction D00836 Buprenorphine 3件: 46, 70, 298
477 OPRK1 1件: Neuroactive ligand-receptor interaction D02095 Naltrexone 4件: 46, 96, 97, 226
478 OPRK1 1件: Neuroactive ligand-receptor interaction D03783 Oxycodone 5件: 46, 70, 226, 231, 298
479 OPRK1 1件: Neuroactive ligand-receptor interaction D05113 Naltrexone 4件: 46, 96, 97, 226
480 OPRK1 1件: Neuroactive ligand-receptor interaction D05312 Oxycodone 5件: 46, 70, 226, 231, 298
481 OPRK1 1件: Neuroactive ligand-receptor interaction D05462 Oxycodone 5件: 46, 70, 226, 231, 298
482 OPRK1 1件: Neuroactive ligand-receptor interaction D07132 Buprenorphine 3件: 46, 70, 298
483 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D00320 Fentanyl 4件: 46, 70, 215, 231
484 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D00836 Buprenorphine 3件: 46, 70, 298
485 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D00842 Morphine 6件: 36, 46, 70, 85, 86, 298
486 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D01355 Tramadol 5件: 46, 70, 78, 226, 271
487 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D01399 Fentanyl 4件: 46, 70, 215, 231
488 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D02095 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
489 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D02271 Morphine 6件: 36, 46, 70, 85, 86, 298
490 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D03783 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
491 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05113 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
492 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05312 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
493 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05462 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
494 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D07132 Buprenorphine 3件: 46, 70, 298
495 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D08233 Morphine 6件: 36, 46, 70, 85, 86, 298
496 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D08623 Tramadol 5件: 46, 70, 78, 226, 271
497 IL20 3件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, JAK-STAT signaling pathway D11756 Fletikumab 1件: 46
498 PDCD1 3件: Cell adhesion molecules, T cell receptor signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer D10316 Nivolumab 12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159
499 PDE2A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
500 PDE2A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
501 PDE3A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
502 PDE3A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
503 PDE3B 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
504 PDE3B 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
505 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00302 Dipyridamole 6件: 46, 49, 51, 66, 96, 224
506 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
507 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
508 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D08860 Apremilast 7件: 46, 50, 56, 97, 107, 162, 271
509 PDE4B 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
510 PDE4B 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
511 PDE4B 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D08860 Apremilast 7件: 46, 50, 56, 97, 107, 162, 271
512 PDE4C 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
513 PDE4C 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
514 PDE4C 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D08860 Apremilast 7件: 46, 50, 56, 97, 107, 162, 271
515 PDE4D 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
516 PDE4D 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
517 PDE4D 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D08860 Apremilast 7件: 46, 50, 56, 97, 107, 162, 271
518 PDE1B 7件: Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
519 PDE1B 7件: Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
520 IL23A 9件: Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis D09214 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
521 PDGFRA 20件: EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D01441 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
522 PDGFRA 20件: EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
523 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D00182 Norethisterone 4件: 13, 46, 49, 299
524 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D00951 Medroxyprogesterone acetate 6件: 13, 35, 46, 49, 51, 60
525 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D00953 Norethisterone 4件: 13, 46, 49, 299
526 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D08166 Medroxyprogesterone acetate 6件: 13, 35, 46, 49, 51, 60
527 PLG 4件: Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Staphylococcus aureus infection, Influenza A D01136 Tranexamic acid 6件: 46, 70, 215, 227, 288, 299
528 POLA1 1件: DNA replication D03546 Clofarabine 6件: 46, 49, 60, 96, 234, 326
529 PPARG 11件: PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D00596 Rosiglitazone 5件: 46, 75, 97, 222, 265
530 PPARG 11件: PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D00945 Pioglitazone 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
531 PPARG 11件: PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D08378 Pioglitazone 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
532 PPARG 11件: PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D08491 Rosiglitazone 5件: 46, 75, 97, 222, 265
533 PPP3CA 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
534 PPP3CA 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
535 PPP3CA 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
536 PPP3CB 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
537 PPP3CB 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
538 PPP3CB 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
539 PPP3CC 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
540 PPP3CC 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
541 PPP3CC 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
542 PPP3R1 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
543 PPP3R1 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
544 PPP3R1 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
545 PPP3R2 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
546 PPP3R2 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
547 PPP3R2 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
548 PRKAA1 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D00944 Metformin 24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
549 PRKAA1 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin 24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
550 PRKAA2 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D00944 Metformin 24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
551 PRKAA2 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin 24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
552 CACNA2D3 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
553 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00267 Chlordiazepoxide 1件: 46
554 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00293 Diazepam 3件: 46, 155, 298
555 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
556 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
557 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00693 Chlordiazepoxide 1件: 46
558 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
559 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem 3件: 5, 6, 46
560 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01514 Etizolam 1件: 46
561 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
562 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
563 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam 3件: 6, 46, 97
564 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem 3件: 5, 6, 46
565 PSMB5 8件: Proteasome, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases D03150 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331
566 PTAFR 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection D07407 Rupatadine 1件: 46
567 PTGER2 6件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels, Renin secretion, Human cytomegalovirus infection, Pathways in cancer D00419 Misoprostol 3件: 46, 70, 271
568 PTGER3 6件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Human cytomegalovirus infection, Pathways in cancer D00419 Misoprostol 3件: 46, 70, 271
569 PTGER4 6件: Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels, Renin secretion, Human cytomegalovirus infection, Human papillomavirus infection, Pathways in cancer D00419 Misoprostol 3件: 46, 70, 271
570 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00109 Acetylsalicylic acid 15件: 13, 22, 34, 46, 49, 51, 58, 86, 96, 97, 113, 158, 210, 231, 251
571 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00118 Naproxen 4件: 13, 46, 107, 271
572 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00126 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
573 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00132 Ketoprofen 1件: 46
574 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00217 Acetaminophen 18件: 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337
575 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00330 Flurbiprofen 3件: 13, 21, 46
576 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00903 Diclofenac 5件: 13, 34, 46, 78, 271
577 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00904 Diclofenac 5件: 13, 34, 46, 78, 271
578 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D01122 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
579 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D01475 Flurbiprofen 3件: 13, 21, 46
580 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D01545 Aceclofenac 1件: 46
581 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D02290 Flurbiprofen 3件: 13, 21, 46
582 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D04490 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
583 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D06606 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
584 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D07816 Diclofenac 5件: 13, 34, 46, 78, 271
585 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D08149 Loxoprofen 2件: 46, 271
586 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00109 Acetylsalicylic acid 15件: 13, 22, 34, 46, 49, 51, 58, 86, 96, 97, 113, 158, 210, 231, 251
587 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00118 Naproxen 4件: 13, 46, 107, 271
588 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00126 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
589 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00132 Ketoprofen 1件: 46
590 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00217 Acetaminophen 18件: 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337
591 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00315 Etodolac 1件: 46
592 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00330 Flurbiprofen 3件: 13, 21, 46
593 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00567 Celecoxib 10件: 2, 3, 34, 46, 70, 89, 107, 161, 171, 271
594 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00568 Rofecoxib 1件: 46
595 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00903 Diclofenac 5件: 13, 34, 46, 78, 271
596 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00904 Diclofenac 5件: 13, 34, 46, 78, 271
597 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00969 Meloxicam 4件: 46, 49, 271, 296
598 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D01049 Nimesulide 1件: 46
599 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D01122 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
600 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D01475 Flurbiprofen 3件: 13, 21, 46
601 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D01545 Aceclofenac 1件: 46
602 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D02290 Flurbiprofen 3件: 13, 21, 46
603 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D02709 Valdecoxib 1件: 46
604 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D03710 Etoricoxib 2件: 46, 271
605 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D03714 Lumiracoxib 1件: 46
606 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D03716 Parecoxib 2件: 46, 271
607 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D04490 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
608 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D06606 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
609 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D07816 Diclofenac 5件: 13, 34, 46, 78, 271
610 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D08149 Loxoprofen 2件: 46, 271
611 PTH1R 3件: Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption D06078 Teriparatide 7件: 46, 65, 68, 70, 71, 235, 274
612 RRM1 5件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways D01907 Fludarabine 19件: 13, 19, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326
613 RRM1 5件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways D03546 Clofarabine 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326
614 RRM1 5件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways D07966 Fludarabine 19件: 13, 19, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326
615 SCN1A 1件: Dopaminergic synapse D00358 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
616 SCN1A 1件: Dopaminergic synapse D01287 Levobupivacaine 1件: 46
617 SCN1A 1件: Dopaminergic synapse D01450 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
618 SCN1A 1件: Dopaminergic synapse D02086 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
619 SCN1A 1件: Dopaminergic synapse D04048 Ropivacaine 2件: 46, 70
620 SCN1A 1件: Dopaminergic synapse D07552 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
621 SCN1A 1件: Dopaminergic synapse D08116 Levobupivacaine 1件: 46
622 SCN1A 1件: Dopaminergic synapse D08127 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
623 SCN1A 1件: Dopaminergic synapse D08490 Ropivacaine 2件: 46, 70
624 SCN2A 1件: Taste transduction D00358 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
625 SCN2A 1件: Taste transduction D01287 Levobupivacaine 1件: 46
626 SCN2A 1件: Taste transduction D01450 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
627 SCN2A 1件: Taste transduction D02086 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
628 SCN2A 1件: Taste transduction D04048 Ropivacaine 2件: 46, 70
629 SCN2A 1件: Taste transduction D07552 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
630 SCN2A 1件: Taste transduction D08116 Levobupivacaine 1件: 46
631 SCN2A 1件: Taste transduction D08127 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
632 SCN2A 1件: Taste transduction D08490 Ropivacaine 2件: 46, 70
633 SCN3A 1件: Taste transduction D00358 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
634 SCN3A 1件: Taste transduction D01287 Levobupivacaine 1件: 46
635 SCN3A 1件: Taste transduction D01450 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
636 SCN3A 1件: Taste transduction D02086 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
637 SCN3A 1件: Taste transduction D04048 Ropivacaine 2件: 46, 70
638 SCN3A 1件: Taste transduction D07299 Lacosamide 2件: 46, 149
639 SCN3A 1件: Taste transduction D07552 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
640 SCN3A 1件: Taste transduction D08116 Levobupivacaine 1件: 46
641 SCN3A 1件: Taste transduction D08127 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
642 SCN3A 1件: Taste transduction D08490 Ropivacaine 2件: 46, 70
643 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00358 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
644 SCN5A 1件: Adrenergic signaling in cardiomyocytes D01287 Levobupivacaine 1件: 46
645 SCN5A 1件: Adrenergic signaling in cardiomyocytes D01450 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
646 SCN5A 1件: Adrenergic signaling in cardiomyocytes D02086 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
647 SCN5A 1件: Adrenergic signaling in cardiomyocytes D04048 Ropivacaine 2件: 46, 70
648 SCN5A 1件: Adrenergic signaling in cardiomyocytes D07552 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
649 SCN5A 1件: Adrenergic signaling in cardiomyocytes D08116 Levobupivacaine 1件: 46
650 SCN5A 1件: Adrenergic signaling in cardiomyocytes D08127 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
651 SCN5A 1件: Adrenergic signaling in cardiomyocytes D08490 Ropivacaine 2件: 46, 70
652 SCN9A 1件: Taste transduction D00358 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
653 SCN9A 1件: Taste transduction D01287 Levobupivacaine 1件: 46
654 SCN9A 1件: Taste transduction D01450 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
655 SCN9A 1件: Taste transduction D02086 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
656 SCN9A 1件: Taste transduction D04048 Ropivacaine 2件: 46, 70
657 SCN9A 1件: Taste transduction D07299 Lacosamide 2件: 46, 149
658 SCN9A 1件: Taste transduction D07552 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
659 SCN9A 1件: Taste transduction D08116 Levobupivacaine 1件: 46
660 SCN9A 1件: Taste transduction D08127 Lidocaine 10件: 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
661 SCN9A 1件: Taste transduction D08490 Ropivacaine 2件: 46, 70
662 CCL2 17件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, NOD-like receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Yersinia infection, Chagas disease, Malaria, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Rheumatoid arthritis, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
663 P2RY12 1件: Platelet activation D09017 Ticagrelor 2件: 46, 85
664 SLC6A2 1件: Synaptic vesicle cycle D00228 Amoxapine 1件: 46
665 SLC6A2 1件: Synaptic vesicle cycle D00821 Venlafaxine 1件: 46
666 SLC6A2 1件: Synaptic vesicle cycle D08222 Milnacipran 2件: 46, 49
667 SLC6A2 1件: Synaptic vesicle cycle D08670 Venlafaxine 1件: 46
668 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D00228 Amoxapine 1件: 46
669 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D00821 Venlafaxine 3件: 6, 13, 46
670 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D00822 Citalopram 7件: 6, 8, 13, 18, 46, 98, 127
671 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D02260 Paroxetine 4件: 6, 13, 46, 85
672 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D02362 Paroxetine 4件: 6, 13, 46, 85
673 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D05374 Paroxetine 4件: 6, 13, 46, 85
674 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D05375 Paroxetine 4件: 6, 13, 46, 85
675 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D07704 Citalopram 7件: 6, 8, 13, 18, 46, 98, 127
676 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D08222 Milnacipran 2件: 46, 49
677 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D08670 Venlafaxine 3件: 6, 13, 46
678 SYK 17件: NF-kappa B signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Platelet activation, Neutrophil extracellular trap formation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Viral carcinogenesis D09347 Fostamatinib 4件: 46, 49, 61, 66
679 ADAM17 4件: Notch signaling pathway, Alzheimer disease, Epithelial cell signaling in Helicobacter pylori infection, Coronavirus disease - COVID-19 D08859 Apratastat 1件: 46
680 BTK 7件: NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency D10893 Acalabrutinib 2件: 46, 61
681 BTK 7件: NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency D11478 Branebrutinib 3件: 46, 49, 53
682 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D00742 Etanercept 17件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298
683 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
684 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D02597 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271
685 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D02598 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
686 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D03441 Certolizumab pegol 8件: 37, 46, 49, 96, 97, 107, 226, 271
687 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D04358 Golimumab 8件: 46, 56, 84, 96, 97, 107, 270, 271
688 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D05393 Pegsunercept 1件: 46
689 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09944 Ozoralizumab 1件: 46
690 TUBB2A 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
691 TUBB2A 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
692 TUBB2A 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
693 TYK2 16件: Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19 D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
694 TYMS 4件: Pyrimidine metabolism, One carbon pool by folate, Metabolic pathways, Antifolate resistance D01244 Tegafur 1件: 46
695 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00129 Calcitriol 9件: 18, 37, 46, 49, 66, 96, 158, 235, 326
696 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00187 Ergocalciferol 6件: 46, 49, 84, 96, 97, 299
697 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00188 Cholecalciferol 25件: 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 75, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299
698 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D01518 Alfacalcidol 8件: 41, 46, 49, 50, 96, 107, 235, 238
699 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D07578 Eldecalcitol 1件: 46
700 XDH 5件: Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome D00224 Allopurinol 6件: 6, 46, 57, 66, 96, 97
701 CACNA2D1 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
702 IL1R2 7件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Amoebiasis, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer, Fluid shear stress and atherosclerosis D02934 Anakinra 19件: 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
703 VKORC1 3件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D00564 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
704 VKORC1 3件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D01280 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
705 VKORC1 3件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D08682 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
706 TUBB1 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
707 TUBB1 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
708 TUBB1 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
709 TUBB6 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel 2件: 46, 85
710 TUBB6 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine 7件: 2, 42, 46, 56, 93, 210, 266
711 TUBB6 10件: Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel 2件: 46, 85
712 TNFSF11 8件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Prolactin signaling pathway, Parathyroid hormone synthesis, secretion and action, Chemical carcinogenesis - receptor activation, Breast cancer, Rheumatoid arthritis D03684 Denosumab 7件: 46, 50, 93, 95, 96, 274, 299
713 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D00302 Dipyridamole 6件: 46, 49, 51, 66, 96, 224
714 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
715 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
716 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02229 Sildenafil 17件: 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
717 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D08514 Sildenafil 17件: 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
718 TNFSF13 3件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, Rheumatoid arthritis D09704 Atacicept 4件: 13, 46, 49, 66
719 CD3D 11件: Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency D08959 Otelixizumab 1件: 46
720 CD3E 11件: Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency D08959 Otelixizumab 1件: 46
721 CD3G 10件: Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer D08959 Otelixizumab 1件: 46
722 CACNA2D2 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
723 MS4A1 1件: Hematopoietic cell lineage D02994 Rituximab 36件: 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
724 MS4A1 1件: Hematopoietic cell lineage D05218 Ocrelizumab 2件: 46, 49
725 MS4A1 1件: Hematopoietic cell lineage D09031 Veltuzumab 1件: 46
726 MS4A1 1件: Hematopoietic cell lineage D09314 Ofatumumab 1件: 46
727 CACNA2D4 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
728 CD80 10件: Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03203 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
729 CD80 10件: Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03222 Belatacept 1件: 46
730 CD86 12件: Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03203 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
731 CD86 12件: Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03222 Belatacept 1件: 46
732 PTGES 2件: Arachidonic acid metabolism, Metabolic pathways D01545 Aceclofenac 1件: 46
733 NR1H4 1件: Bile secretion D00734 Ursodeoxycholic acid 11件: 46, 67, 84, 93, 94, 95, 96, 97, 234, 296, 299